法国医疗保险数据库中银屑病及银屑病关节炎患者一线生物制剂长期持续性的研究
该法国全国队列研究纳入2015年1月1日至2019年5月31日新使用生物制剂的成人银屑病(PsO)患者16892例和银屑病关节炎(PsA)患者6531例,随访至2019年12月31日。结果显示PsO和PsA的3年总体持续率分别为40.9%和36.2%;在白介素17(IL-17)抑制剂与肿瘤坏死因子(TNF)抑制剂比较中,PsO的加权风险比(HR)为0.78(95%CI 0.73-0.83),PsA为0.70(95%CI 0.58-0.85),均提示IL-17抑制剂与更高的持续性相关。
要点
- PsO和PsA的3年总体生物制剂持续率分别为40.9%和36.2%。
- PsO中IL-17抑制剂较TNF抑制剂持续性更高(加权HR 0.78,95%CI 0.73-0.83)。
- PsA中IL-17抑制剂较TNF抑制剂持续性更高(加权HR 0.70,95%CI 0.58-0.85)。
核心结论
- 该队列研究提示,对于PsO和PsA,IL-17抑制剂与比TNF抑制剂更高的治疗持续性相关。
- 对于PsA,IL-17抑制剂也与比IL-12/23抑制剂更高的持续性相关,而在PsO中两者无差异。
- 然而,所有生物制剂的3年持续率总体仍较低。
研究设计与样本
- 法国全国队列研究,使用法国医疗保险计划行政医疗数据库并链接医院出院数据库。
- 纳入2015年1月1日至2019年5月31日新使用生物制剂的成人PsO和PsA患者,随访至2019年12月31日。
- 排除索引日期前一年因PsA住院的PsO队列患者和因PsO住院的PsA队列患者。
- 数据分析时间为2021年6月1日至10月31日。
- 采用Kaplan-Meier法估计持续性,并使用倾向评分加权Cox比例风险回归模型比较不同生物制剂类别的持续性,同时对特定系统性非生物制剂(时变变量)进行调整。
主要发现
- 共纳入16892例PsO患者(平均[SD]年龄48.5[13.8]岁;9152例男性[54.2%]);其中10199例(60.4%)开始TNF抑制剂治疗,3982例(23.6%)开始IL-12/23抑制剂治疗,2711例(16.0%)开始IL-17抑制剂治疗。
- 共纳入6531例PsA患者(平均[SD]年龄49.1[12.8]岁;3565例女性[54.6%]);其中4974例(76.2%)开始TNF抑制剂治疗,803例(12.3%)开始IL-12/23抑制剂治疗,754例(11.5%)开始IL-17抑制剂治疗。
- PsO和PsA的总体3年持续率分别为40.9%和36.2%。
- 在逆概率处理加权和调整后,对于PsO,IL-17抑制剂相比TNF抑制剂与更高的持续性相关(加权HR 0.78[95%CI 0.73-0.83]);对于PsA,IL-17抑制剂相比TNF抑制剂与更高的持续性相关(加权HR 0.70[95%CI 0.58-0.85]),相比IL-12/23抑制剂也与更高的持续性相关(加权HR 0.69[95%CI 0.55-0.87])。
- 对于PsO,IL-17抑制剂与IL-12/23抑制剂之间无差异;对于PsO,IL-12/23抑制剂相比TNF抑制剂与更高的持续性相关(加权HR 0.76[95%CI 0.72-0.80]),而在PsA中未观察到差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Treatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved significantly throughout the era of biologics. Clinical trials are inadequate to assess the relative long-term efficacy of biologics and are often insufficient regarding safety. OBJECTIVES: To assess the long-term persistence of different biologic classes to treat PsO and PsA. DESIGN, SETTING, AND PARTICIPANTS: This nationwide cohort study involved the administrative health care database of the French health insurance scheme linked to the hospital discharge database. All adults with PsO and PsA who were new users of biologics (not in the year before the index date) from January 1, 2015, to May 31, 2019, were included and followed up through December 31, 2019. Patients hospitalized for PsA in the PsO cohort and for PsO in the PsA cohort in the year before the index date were excluded. Data were analyzed from June 1 to October 31, 2021. MAIN OUTCOMES AND MEASURES: Persistence was defined as the time from biologic therapy initiation to discontinuation and was estimated using the Kaplan-Meier method. Comparison of persistence by biologic class involved using propensity score-weighted Cox proportional hazards regression models and adjustment on specific systemic nonbiologics (time-dependent variables). RESULTS: A total of 16 892 patients with PsO were included in the analysis (mean [SD] age, 48.5 [13.8] years; 9152 men [54.2%] men). Of these, 10 199 patients (60.4%) started therapy with a tumor necrosis factor (TNF) inhibitor; 3982 (23.6%), with an interleukin 12 and interleukin 23 (IL-12/23) inhibitor; and 2711 (16.0%), with an interleukin 17 (IL-17) inhibitor. An additional 6531 patients with PsA (mean [SD] age, 49.1 [12.8] years; 3565 [54.6%] women) were included; of these, 4974 (76.2%) started therapy with a TNF inhibitor; 803 (12.3%), with an IL-12/23 inhibitor; and 754 (11.5%), with an IL-17 inhibitor. Overall 3-year persistence rates were 40.9% and 36.2% for PsO and PsA, respectively. After inverse probability of treatment weighting and adjustment, the IL-17 inhibitor was associated with higher persistence compared with the TNF inhibitor for PsO (weighted hazard ratio [HR], 0.78 [95% CI, 0.73-0.83]) and PsA (weighted HR, 0.70 [95% CI, 0.58-0.85]) and compared with the IL-12/23 inhibitor for PsA (weighted HR, 0.69 [95% CI, 0.55-0.87]). No difference between the IL-17 inhibitor and IL-12/23 inhibitor for PsO was noted. The IL-12/23 inhibitor was associated with higher persistence than the TNF inhibitor for PsO (weighted HR, 0.76 [95% CI, 0.72-0.80]), with no difference observed for PsA. CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that IL-17 inhibitors are associated with higher treatment persistence than the TNF inhibitor for PsO and PsA. Interleukin 17 inhibitors were also associated with higher persistence than the IL-12/23 inhibitor for PsA, with no difference for PsO. However, the persistence rates of all biologics remained globally low at 3 years.
引用
- Pina Vegas L, Penso L, Claudepierre P, et al. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database. JAMA Dermatol. 2022. PMID: 35319735. doi:10.1001/jamadermatol.2022.0364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。